

Table 3. Demographic of patients with clinical BCRL diagnosed by physician.

	<b>BCRL (n=33)</b>	<b>No BCRL (n=478)</b>	<b>P value</b>
Age, median (years)	61.1 ± 12.9	55.6 ± 12.5	0.02
BMI	27.2 ± 8.3	25.9 ± 7.6	0.38
Breast surgery			0.02
BCS	2 (6.5%)	133 (29.4%)	
Mastectomy	29 (93.5%)	320 (70.6%)	
Axillary surgery			0.008
SLNB/Axillary sampling	5 (16.7%)	205 (47.3%)	
Axillary clearance	25 (83.3%)	228 (52.7%)	
Reconstruction	0	48	0.02
Time interval from operation, months	84.6 ± 15.5	89.0 ± 3.5	0.75
Histology			0.29
DCIS	3 (9.1%)	84 (17.6%)	
Ductal	23 (69.7%)	294 (61.7%)	
Lobular	0	23 (4.8%)	
Others	7 (21.2%)	76 (15.9%)	
Grade			0.05
1	0	72 (15.8%)	
2	15 (50.0%)	211 (46.4%)	
3	15 (50.0%)	172 (37.8%)	
Tumour stage			0.005
0	6 (18.2%)	103 (21.6%)	
1	4 (12.1%)	171 (35.8%)	
2	15 (45.6%)	162 (33.9%)	
3	5 (15.5%)	31 (6.5%)	
4	3 (9.1%)	11 (2.3%)	
Nodal stage			<0.001
0	16 (48.5%)	350 (73.2%)	
1	6 (18.2%)	87 (18.2%)	
2	6 (18.2%)	25 (5.2%)	
3	5 (15.2%)	16 (3.4%)	
No. of lymph node positive, mean	5 ± 8	1.2 ± 3.5	<0.001
No. of lymph node excised, mean	16.9 ± 8.9	11.4 ± 8.4	<0.001
NPI			0.001
Good	4 (12.9%)	147 (31.6%)	
Moderate	12 (38.7%)	202 (43.4%)	
Poor	12 (38.7%)	60 (12.9%)	
Receptor profile			0.43
ER+	21 (72.4%)	361 (78.7%)	
TNBC	4 (12.2%)	35 (7.3%)	
Her2+	7 (24.1%)	110 (25.3%)	
Adjuvant chemotherapy	24 (72.7%)	232 (48.6%)	0.007
Adjuvant endocrine therapy	21 (63.6%)	331 (69.3%)	0.51
Adjuvant radiotherapy	20 (60.6%)	227 (47.5%)	0.15

BCS: breast-conserving surgery; BMI: body mass index (kg/m<sup>2</sup>); DCIS: ductal carcinoma-in-situ; ER: estrogen receptor positive; Her2+: human epidermal growth factor receptor 2 positive; NPI: Nottingham Prognostic Index; SLNB: sentinel lymph node biopsy; TNBC: triple negative breast cancer